Login | Signup

Square Enix: £20 Mobile Titles "Haven't Had The Negative Sales Response Some Would Think"

Matt Gardner
Android, Final Fantasy Dimensions, iOS, Mobile games, Mobile pricing, Sales, Square Enix

Square Enix: £20 Mobile Titles "Haven't Had The Negative Sales Response Some Would Think"

Square Enix have come under a little bit of fire for having the gall to release games on services such iOS and Android at comparatively super-premium rates. The recent Final Fantasy Dimensions, for example, hit the App Store at £19.99.

However, the company have suggested that such premium pricing has turned over more revenue than plenty of free-to-play titles, saying that the sales response has been far from negative.

“It’s actually done a lot more revenue than a lot of free-to-play with in-app purchases or advertising models,” said Square Enix’s mobile general manager Antony Douglas, chatting to MCV. “You’ve got to sell 12 times that in some cases to get to one game on that £14.99/£20 model. Customer behaviour is changing all the time so it’s one of many business models that we have and we have all the others under scrutiny as well."

“What I will say about the business model is that it’s not fixed. Everyone says free-to-play is the future and that’s absolutely part of it, but that will change. If you’re playing a lengthy £20 RPG title, there will be an audience for that. Some people won’t go for it but those people could spend £30 on resource management games. We’re looking into it to see how people respond.

“We can’t show too much in the way of figures but it hasn’t had the negative sales response that some people would think.”

Of course, it's  impossible not to factor in the importance of the Square Enix brand, and the Final Fantasy name. Just because you might be able to squeeze more money out of people, doesn't necessarily mean that you should.

Add a comment0 comments


Leave a Trackback from your own site

Email Address:

You don't need an account to comment. Just enter your email address. We'll keep it private.